Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 4348

1.

Production of lentiviral vectors using novel, enzymatically produced, linear DNA.

Karda R, Counsell JR, Karbowniczek K, Caproni LJ, Tite JP, Waddington SN.

Gene Ther. 2019 Jan 14. doi: 10.1038/s41434-018-0056-1. [Epub ahead of print]

PMID:
30643205
2.

Correction: Epistasis between Pax6Sey and genetic background reinforces the value of defined hybrid mouse models for therapeutic trials.

Hickmott JW, Gunawardane U, Jensen K, Korecki AJ, Simpson EM.

Gene Ther. 2019 Jan 2. doi: 10.1038/s41434-018-0054-3. [Epub ahead of print]

PMID:
30602728
3.

Histone deacetylase inhibitors reactivate silenced transgene in vivo.

Zhang C, Zhang G, Liu D.

Gene Ther. 2018 Dec 11. doi: 10.1038/s41434-018-0053-4. [Epub ahead of print]

PMID:
30538307
4.

GDNF-mediated rescue of the nigrostriatal system depends on the degree of degeneration.

Quintino L, Avallone M, Brännstrom E, Kavanagh P, Lockowandt M, Garcia Jareño P, Breger LS, Lundberg C.

Gene Ther. 2018 Dec 7. doi: 10.1038/s41434-018-0049-0. [Epub ahead of print]

PMID:
30531868
5.

Immunosuppression overcomes insulin- and vector-specific immune responses that limit efficacy of AAV2/8-mediated insulin gene therapy in NOD mice.

Recino A, Gan SU, Sia KC, Sawyer Y, Trendell J, Kay R, Gribble FM, Reimann F, Foale R, Notaridou M, Holmes N, Lever A, Lee KO, Nathwani A, Cooke A, Calne R, Wallberg M.

Gene Ther. 2018 Dec 4. doi: 10.1038/s41434-018-0052-5. [Epub ahead of print]

PMID:
30514969
6.

Unilateral ex vivo gene therapy by GDNF in epileptic rats.

Nanobashvili A, Melin E, Emerich D, Tornøe J, Simonato M, Wahlberg L, Kokaia M.

Gene Ther. 2018 Nov 21. doi: 10.1038/s41434-018-0050-7. [Epub ahead of print]

PMID:
30464254
7.

HIV infection alters the human epigenetic landscape.

Chen L, Zhang S, Pan X, Hu X, Zhang YH, Yuan F, Huang T, Cai YD.

Gene Ther. 2018 Nov 15. doi: 10.1038/s41434-018-0051-6. [Epub ahead of print]

PMID:
30443044
8.

Osteoinduction within BMP-2 transduced muscle tissue fragments with and without a fascia layer: implications for bone tissue engineering.

Ren B, Betz VM, Thirion C, Salomon M, Jansson V, Müller PE, Betz OB.

Gene Ther. 2018 Oct 27. doi: 10.1038/s41434-018-0047-2. [Epub ahead of print]

PMID:
30368527
9.

Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy.

Mukhopadhyay A, Wright J, Shirley S, Canton DA, Burkart C, Connolly RJ, Campbell JS, Pierce RH.

Gene Ther. 2018 Oct 15. doi: 10.1038/s41434-018-0044-5. [Epub ahead of print]

PMID:
30323352
10.

An important step on the long path to clinical application of in utero gene therapy.

Coutelle C.

Gene Ther. 2018 Oct;25(7):451-453. doi: 10.1038/s41434-018-0046-3. Epub 2018 Oct 5. No abstract available.

PMID:
30291314
11.

Long noncoding RNA Meg3 regulates cardiomyocyte apoptosis in myocardial infarction.

Wu H, Zhao ZA, Liu J, Hao K, Yu Y, Han X, Li J, Wang Y, Lei W, Dong N, Shen Z, Hu S.

Gene Ther. 2018 Dec;25(8):511-523. doi: 10.1038/s41434-018-0045-4. Epub 2018 Oct 4.

PMID:
30287867
12.

Epistasis between Pax6Sey and genetic background reinforces the value of defined hybrid mouse models for therapeutic trials.

Hickmott JW, Gunawardane U, Jensen K, Korecki AJ, Simpson EM.

Gene Ther. 2018 Dec;25(8):524-537. doi: 10.1038/s41434-018-0043-6. Epub 2018 Sep 26. Erratum in: Gene Ther. 2019 Jan 2;:.

13.

Improved therapeutic potential of MSCs by genetic modification.

Wei W, Huang Y, Li D, Gou HF, Wang W.

Gene Ther. 2018 Dec;25(8):538-547. doi: 10.1038/s41434-018-0041-8. Epub 2018 Sep 25.

PMID:
30254305
14.

Anti-angiogenic treatment of endometriosis via anti-VEGFA siRNA delivery by means of peptide-based carrier in a rat subcutaneous model.

Egorova A, Petrosyan M, Maretina M, Balashova N, Polyanskih L, Baranov V, Kiselev A.

Gene Ther. 2018 Dec;25(8):548-555. doi: 10.1038/s41434-018-0042-7. Epub 2018 Sep 25.

PMID:
30254304
15.

Scaffold-mediated delivery for non-viral mRNA vaccines.

Chen R, Zhang H, Yan J, Bryers JD.

Gene Ther. 2018 Dec;25(8):556-567. doi: 10.1038/s41434-018-0040-9. Epub 2018 Sep 21.

16.

Superior lentiviral vectors designed for BSL-0 environment abolish vector mobilization.

Hu P, Bi Y, Ma H, Suwanmanee T, Zeithaml B, Fry NJ, Kohn DB, Kafri T.

Gene Ther. 2018 Oct;25(7):454-472. doi: 10.1038/s41434-018-0039-2. Epub 2018 Sep 6.

PMID:
30190607
17.

Metabolically stabilized double-stranded mRNA polyplexes.

Poliskey JA, Crowley ST, Ramanathan R, White CW, Mathew B, Rice KG.

Gene Ther. 2018 Oct;25(7):473-484. doi: 10.1038/s41434-018-0038-3. Epub 2018 Aug 28.

PMID:
30154525
18.

In vivo delivery of pPERDBY to BALB/c mice by LacVax® DNA-I and comparison of elicited immune response with conventional immunization methods.

Yagnik B, Sharma D, Padh H, Desai P.

Gene Ther. 2018 Oct;25(7):485-496. doi: 10.1038/s41434-018-0033-8. Epub 2018 Aug 14.

PMID:
30108273
19.

Diabetic complication could get a gene therapy boost.

Castañeda-Delgado JE.

Gene Ther. 2018 Sep;25(6):401. doi: 10.1038/s41434-018-0037-4. Epub 2018 Aug 10. No abstract available.

PMID:
30097613
20.

Ectopic BAT mUCP-1 overexpression in SKM by delivering a BMP7/PRDM16/PGC-1a gene cocktail or single PRMD16 using non-viral UTMD gene therapy.

Chen S, Bastarrachea RA, Shen JS, Laviada-Nagel A, Rodriguez-Ayala E, Nava-Gonzalez EJ, Huang P, DeFronzo RA, Kent JW Jr, Grayburn PA.

Gene Ther. 2018 Oct;25(7):497-509. doi: 10.1038/s41434-018-0036-5. Epub 2018 Aug 2.

PMID:
30072816

Supplemental Content

Loading ...
Support Center